Replies to post #328919 on Avid Bioservices Inc (CDMO)

[biopharm]

Hutschi, I wonder if PS Targeting research info and data was disclosed by either Allison or Honjo since any new knowledge gained via PS Targeting research data was possibly able to allow further scientific advancements ....

PS Targeting patents all seem to be the key

Nivolumab (nye vol' ue mab; ONO-4538, BMS-936558, or MDX1106), marketed as Opdivo, is a human IgG4 anti-PD-1 monoclonal antibody developed by Ono Pharmaceutical and Medarex (later acquired by Bristol-Myers Squibb) for the treatment of cancer.[1][2] Nivolumab acts as an immunomodulator by blocking ligand activation of the programmed cell death 1 (PD-1) receptor on activated T cells.
...
...

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=118427232